Cannabinoid Safety and Regulation Act
- Bill Number
- S. 3474
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-15: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-01-14T12:03:37Z
AI-Generated Summary
Purpose of the Legislation
The Cannabinoid Safety and Regulation Act (S. 3474) aims to create a federal framework for regulating cannabis-derived products, known as cannabinoid products (e.g., those containing CBD or THC from hemp). It focuses on ensuring product safety, accurate labeling, and manufacturing standards through the Food and Drug Administration (FDA), while promoting public health measures to prevent underage use and addressing risks like impaired driving. The goal is to treat these products like other consumer goods (e.g., foods or supplements) rather than controlled substances, without legalizing recreational cannabis cultivation.
Key Provisions
The bill is divided into three titles, amending the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related laws.
Title I: FDA Regulation of Cannabinoid Products
- Definitions and Scope: Defines "cannabinoid products" as items containing hemp-derived cannabinoids (e.g., THC, CBD) intended for human or animal use, excluding approved drugs or devices. "Cannabis" excludes regulated hemp plants and low-THC products. THC includes various forms (natural or synthetic).
- Adulterated Products: Products are adulterated if contaminated, produced in unsanitary conditions, containing unsafe additives, synthetic cannabinoids, or exceeding state THC limits (or federal defaults if states lack rules).
- Misbranded Products: Requires detailed labeling, including cannabinoid content (in mg per serving), warnings for children/pregnant users, drug interaction risks, FDA non-approval statement, and a universal symbol for intoxicating/non-intoxicating products. Prohibits child-appealing shapes, flavors mimicking candy, or forms like eye drops/injectables (except approved ones). Allows use of the term "cannabis" without misbranding.
- Registration and Oversight: Facilities manufacturing or handling these products must register with FDA (with fees up to $500, adjustable for inflation), list products, and allow inspections. FDA can suspend registrations for safety risks and require recalls for products posing serious harm (e.g., death or hospitalization).
- Manufacturing and Testing: Mandates "good manufacturing practices" (clean production standards) and "good testing practices" (lab accreditation, testing for pesticides, heavy metals, potency). Establishes product standards for ingredients, testing, and serving sizes (e.g., max 5 mg THC per serving, 50 mg per container for most categories; lower for drinks). Prohibits flavored electronic delivery systems (vapes) except limited terpenes (plant compounds for flavor/scent).
- Sales Restrictions: Bans sales to those under 21, requires age verification for online/remote sales, and mandates child-resistant packaging for multi-serving products. Allows cannabinoids in foods/supplements if they meet all rules, without automatic adulteration.
- Special Report: Agencies (USDA, FDA, DOJ, Alcohol and Tobacco Tax Bureau) must recommend regulations for THC-containing beverages, modeled on alcohol rules.
Title II: Public Health
- Surveillance: Expands CDC data collection on cannabis use effects, polysubstance use (mixing with other drugs), and health risks; increases funding from $496M to $596M annually (FY2026–2030), plus $100M extra per year.
- Underage Prevention Grants: Awards $25M annually (FY2026–2030) to states, tribes, nonprofits for education, screening, community programs targeting youth (especially underserved or high-risk areas). Prioritizes areas with high underage use or past disproportionate arrests for cannabis offenses (excluding sales to minors).
Title III: Cannabis-Impaired Driving Prevention
- Research: DOT must conduct a National Roadside Survey on THC-positive drivers, study crash risks, impairment correlations (e.g., THC levels vs. driving behavior), and effects of mixing cannabis with other substances. Annual reports to Congress; $30M funding (FY2026–2030).
- Education and Best Practices: Develops/update national campaigns and state guides on preventing impaired driving, targeting youth and polysubstance use. Evaluates effectiveness every 3 years.
- State Grants: $40M annually (FY2026–2030) for enforcement (e.g., training officers, lab upgrades), data collection, and education. Requires 10% for toxicology labs; federal share starts at 80% but drops if states lack cannabis "open container" laws.
- Impairment Standard: DOT assesses feasibility of a national THC impairment threshold (e.g., blood/oral fluid levels) every 2 years; if feasible, issues model rules for states within 1 year.
Significant Changes to Existing Law
- FD&C Act Amendments: Adds Chapter XI for cannabinoids, integrating them into food/supplement rules without deeming them inherently unsafe (unlike current vague status under drug laws). Updates definitions (e.g., excludes cannabinoids from "drug" or "tobacco" categories), prohibited acts (e.g., bans sales to minors, adulterated products), penalties (up to $15,000/violation, $250,000 for knowing violations; "no-sales" orders for repeat offenders), seizure/inspection powers, and import/export rules.
- No Preemption on Most State Laws: Preserves state/tribal authority for stricter rules (e.g., bans, taxes), but mandates identical federal labeling. Prohibits states/tribes from blocking compliant product transport.
- Hemp Distinction: Builds on 2018 Farm Bill by regulating hemp-derived (low-THC) products federally, excluding active hemp cultivation from FDA oversight (left to USDA).
- Funding and Timelines: Introduces new appropriations ($195M+ annually) and deadlines (e.g., regulations within 1–3 years).
Potential Impacts
- Government Agencies: FDA gains broad authority/enforcement tools, increasing workload/budget (e.g., registrations, testing oversight). HHS/CDC expands health tracking; DOT/NHTSA focuses on road safety research/grants. USDA retains hemp farming role; interagency coordination required for beverages.
- Citizens: Improves product safety/transparency (e.g., potency labels, contaminant tests), reduces youth access/risks via age gates and education. May lower black-market dangers but raise costs for compliant products. Enhances driving safety through better detection/enforcement, potentially reducing THC-related crashes.
- International Relations: Affects imports (e.g., foreign facilities must register/test; uniform standards for foreign-grown hemp). Could harmonize U.S. rules with global markets, easing trade but requiring compliance for exporters.
Main Stakeholders Affected
- Industry Players: Manufacturers, importers, distributors, retailers of cannabinoid products (e.g., edibles, vapes, topicals) must register, test, and label, facing fees/penalties but gaining legal clarity.
- Consumers: Especially youth, pregnant individuals, and drivers; benefits from warnings and restrictions but may see limited access in strict states.
- Governments: States/tribes/localities (grants, preserved authority); federal agencies (new duties/funding).
- Public Health and Safety Groups: Healthcare providers, law enforcement, labs (training, data needs); communities with high use/arrest histories (targeted prevention).
- Farmers/Producers: Hemp growers (unaffected directly, but downstream products regulated).
Notable Legal, Constitutional, or Political Implications
- Legal: Shifts cannabinoids from Schedule I drug status (under Controlled Substances Act) to consumer product regulation, potentially reducing federal-state conflicts in legal cannabis states. Enables lawsuits under state product liability laws unchanged. Recall/seizure powers strengthen FDA enforcement without new criminal penalties.
- Constitutional: Relies on Commerce Clause for interstate regulation; preserves state sovereignty (10th Amendment) by allowing stricter local rules, avoiding preemption challenges. Tribal consultations ensure compliance with federal Indian law.
- Political: Neutralizes debates on cannabis by focusing on safety over legalization, appealing to health-focused lawmakers. Addresses equity (e.g., prioritizing high-arrest communities) amid growing state markets (e.g., 24+ states allow recreational use). May face opposition from anti-cannabis groups over perceived promotion, or industry over costs; supports bipartisan road safety goals.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Merkley, Jeff [D-OR], Sen. Smith, Tina [D-MN]
Recent Actions
- 2025-12-15: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-12-15: Introduced in Senate
Bill Versions
- Cannabinoid Safety and Regulation Act — issued 2025-12-15 — PDF (84 pages)